COPD

May 31, 2023

DUPIXENT has shown positive pivotal results for COPD, confirming the key role of IL-4 and IL-13 in type 2 inflammatory diseases. DUPIXENT has the potential to be the first biologic with unprecedented and paradigm-shifting clinical results to treat COPD, having demonstrated a statistically significant reduc...

Apr 11, 2023

FDA Grants Orphan Drug Designation to Osemitamab for Pancreatic Cancer Transcenta Holding Limited has announced that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to Osemitamab (TST001), a highly potent humanized monoclonal antibody that enhances ADCC (antibody-dependent cell-me...

Sep 15, 2022

Johnson & Johnson Vision Launches New Contact Lens Innovation ACUVUE® OASYS MAX 1-Day for Meeting the Needs of Digitally Intense Lifestyles On September 12, 2022, Johnson & Johnson Vision, a part of Johnson & Johnson and a global leader in the eyecare market, had announced the launch of its newest in...

Aug 30, 2022

Aktis Oncology Raises USD 84 Million To Advance Novel Targeted Alpha Radiopharmaceuticals Aktis Oncology has raised an additional USD 84 million in its Series A round, adding to the USD 72 million raised last year to help bring its radiopharmaceuticals to market. The extension to the first round included Merck's...

May 11, 2022

Over the past few years, the prevalence of the chronic disease has grown significantly. The rising prevalence is leading to a severe social and economical burden on the individuals and their families. Chronic diseases are long-lasting conditions with endless side effects associated with them. Despite the rise in mo...

Apr 08, 2022

Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death across the globe. It is a widespread, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow restriction caused by airway and alveolar abnormalities, which are mainly induced by prolonged exposu...

Mar 22, 2022

NHS Grants Fast Track Access to Takeda’s Exkivity Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks. The Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorisa...

May 26, 2021

Today, the increasing prevalence of Chronic Respiratory Diseases (CRDs) is one of the leading health challenges worldwide. CRDs affect hundreds of millions of people and cause huge mortality, morbidity, immense socio-economic burden, and disability-adjusted life years (DALYs).  Over the past few decades, si...

Feb 03, 2020

Nontuberculous Mycobacteria (NTM) is a ubiquitous, aerobic, non-motile, acid-fast bacteria, which, when inhaled, may cause severe lung disorders. Especially common in the elderly, individuals with lung diseases, slender caucasian women, and people with esophageal disorders, NTM affects both healthy persons and thos...

Nov 15, 2019

Levels of air pollution have risen dramatically over the past years due to increasing outdoor human activities such as industrialization, urbanization and indoor activities like burning of solid fuels, coal, etc. This has contaminated the air we breathe with several harmful substances such as Sulfur dioxide (SO2), ...